Objective:
To assess the effects of 90 days of oral Pep19 on regional fat distribution, metabolic measures, and safety in adults with obesity.
Approach:
- Design and participants: Randomized, double-blind, placebo-controlled trial of 60 adults aged 21–60 years with obesity; 56 completed the study.
- Intervention and outcomes: Participants received Pep19 5 mg, Pep19 10 mg, or placebo once daily. The primary endpoint was change in the DXA-measured android-to-gynoid fat ratio at day 90.
Key Findings:
- Pep19 10 mg reduced the android-to-gynoid fat ratio versus placebo by an adjusted 3.58 percentage points; the 5-mg dose did not significantly affect the primary endpoint.
- The 10-mg dose was associated with reduced abdominal and total skinfold thickness, but body weight, BMI, total fat mass, and lean mass did not differ significantly between groups.
- HbA1c and HOMA-IR improved in Pep19 groups, while fasting glucose remained unchanged. These were secondary outcomes.
- Lipid profiles, inflammatory biomarkers, and blood pressure showed no significant between-group differences.
- No treatment-related toxicologic signals or clinically relevant laboratory abnormalities were identified during the 90-day study.
Interpretation:
The authors stated that the findings support improved metabolic regulation, but do not provide definitive proof of improved insulin sensitivity.
Limitations:
- The sample was modest and follow-up was limited to 90 days.
- The primary endpoint was significant as a percentage of baseline, but not in the supporting absolute-scale analysis.
- HbA1c and HOMA-IR findings were secondary; baseline insulin resistance was higher in the 10-mg group.
- Diet and physical activity were not objectively monitored, and target engagement or other mechanistic biomarkers were not assessed.
- The exploratory responder analysis and recruitment from one geographic setting limit generalizability.
Conclusion:
Larger, longer-term trials are needed to assess whether the observed changes persist and translate into meaningful cardiometabolic benefits.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
